--- title: How to Improve Diversity in Clinical Trials Without Slowing Progress description: Improve diversity in clinical trials without delaying timelines. Discover strategies that boost retention and help sponsors meet representation goals. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Improve-Diversity-in-Clinical-Trials-Without-Slowing-Progress.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # Improve Diversity in Clinical Trials Without Slowing Progress Improve diversity in clinical trials without delaying timelines. Discover strategies that boost retention and help sponsors meet representation goals. ![Improve Diversity in Clinical Trials Without Slowing Progress](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Improve-Diversity-in-Clinical-Trials-Without-Slowing-Progress.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/diversify-clinical-trials-without-slowing-progress-acclinate) [**](https://twitter.com/home?status=https://blog.acclinate.com/diversify-clinical-trials-without-slowing-progress-acclinate) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/diversify-clinical-trials-without-slowing-progress-acclinate&title=How%20to%20Improve%20Diversity%20in%20Clinical%20Trials%20Without%20Slowing%20Progress) Stay up to date Get news directly in your inbox **Key Takeaways and Learnings**  - The belief that representation slows clinical trials is outdated—early inclusion strategies often speed them up. - Retention, recruitment stability, and data quality all improve when communities of color are engaged from the start. - Acclinate’s **NOWINCLUDED** platform and **e-DICT™** analytics make representation both efficient and effective. - [**Check out our case studies**](https://www.acclinate.com/case-studies) to see how Acclinate helped a sponsor exceed both diversity and enrollment goals while staying ahead of schedule.    For years, there’s been a quiet but persistent belief in clinical research: if you want a trial to move quickly, you have to limit the complexity of participant outreach. That often means drawing from the most accessible populations, which in practice can lead to underrepresentation of specific communities.  The logic seems straightforward—broadening recruitment takes more time, right? But experience and evidence tell a different story. In reality, when representation is integrated into a trial from the beginning, recruitment can become more efficient, timelines more predictable, and participant retention stronger.  Far from being a burden, inclusion can be one of the most effective tools to accelerate research. Achieving this means shifting how we think about outreach, building trust with participants who have historically been excluded, and using technology to make that trust actionable.  It’s time to retire the myth that representation slows trials. When done right, it keeps trials on schedule and can help them finish ahead of it. [![Download Now – Increasing Diversity in Clinical Trials: A Comprehensive Guide for Pharma Companies](https://no-cache.hubspot.com/cta/default/19943632/interactive-169988622868.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJzysiN9lDRuH8jidbYBndDLrU7d1YcnHqhj6TtN35%2B0UFs04LZbrp4NljSJbLm4J5xiueSn5vPeJdLWAI%2FRMPALc3SEu%2FTReYOhfQpTO0ZfsHaiZIKn40MCPjY8QKqtwI5IfTPbMrCsie7tIUtZPXahMizAzB%2BXXE1A8CqDM%2FIdfp%2BkBC%2BuPlat1Pr6pkuSSnFhcSSKNvkcTbMPB2h17qjci%2FN3e536sVfPQ%3D%3D&webInteractiveContentId=169988622868&portalId=19943632) ## Why the “Speed vs. Representation” Myth Persists Clinical research sponsors and CROs operate under intense time pressure. The sooner a trial reaches full enrollment, the sooner it can move to completion, regulatory review, and—if successful—market launch. This urgency leads many to lean heavily on participant pools that are easy to reach through existing site relationships or patient databases.  On paper, that can seem like the fastest route. In practice, it often results in trials that stall midstream when enrollment targets aren’t met or dropout rates spike. The numbers might look good in the first few weeks, but without a diverse and engaged participant base, trials can hit costly slowdowns that take months to recover from.  For communities of color, a mix of historical mistrust, lack of culturally relevant outreach, and limited awareness of research opportunities has created additional barriers to participation. These aren’t issues that can be solved with a last-minute recruitment push—they require thoughtful, relationship-driven engagement from the start.  Because building those relationships takes effort, some sponsors misinterpret long-term investment in representation as a delay. The truth is that skipping initiatives for inclusion can be the real time sink.  ## **Inclusion as a Driver of Efficiency**  When representation is prioritized early, it creates ripple effects that make the entire trial more efficient. Three benefits stand out:  ### 1. Higher Retention Rates Participants who feel informed, respected, and culturally understood are more likely to stay enrolled. A trial that starts strong, but loses participants mid-way, faces delays in backfilling spots and risks underpowered results. Retention is the quiet time-saver that many overlook.  ### 2. Reduced Recruitment Gaps Casting a wider, more inclusive net early means you’re less likely to face last-minute scrambles to meet enrollment numbers. That stability keeps trial timelines predictable.  ### 3. Better Data Quality A more representative sample reduces the likelihood of post-study requirements to validate findings across missing populations. That means fewer follow-up studies and a faster path to approval. Evidence backs this up. For example, [one analysis](https://www.ncbi.nlm.nih.gov/books/NBK584396/) found that proactive inclusion strategies not only improve diversity in clinical trials but also help studies recruit faster, meet enrollment targets more efficiently, and avoid costly delays or early termination.   [Download our ultimate guide to advancing health equity in clinical trials for a deeper dive](https://info.acclinate.com/ebook-ultimate-guide-to-advancing-health-equity-in-clinical-trials). ## **The Hidden Costs of Undervaluing Representation** When representation is treated as an afterthought, trials can face:  - **Enrollment Delays**: Narrow outreach often means early numbers look good, but stall once the easily reachable participants are enrolled. - **Increased Dropout Rates**: Without culturally relevant engagement, participants may feel disconnected and exit before completion. - **Regulatory Setbacks**: As regulatory agencies continue to emphasize diversity in trial participation, studies that fail to meet representation guidelines risk additional scrutiny or delays.  Each of these factors can add weeks or months to a study’s timeline—far more than the time required to design inclusive strategies from the start.  ## How Acclinate Helps With Accelerating Inclusive Research Acclinate partners with sponsors, CROs, and research sites to make inclusion both intentional and efficient. Our approach is rooted in trust, supported by technology, and proven to deliver results without slowing down timelines.  - **NOWINCLUDED** – Our trusted health community platform empowers underrepresented community members to access reliable information, share experiences, and learn about research opportunities that matter to them. It’s a culturally safe space where trust is built through conversation. - **e-DICT™** – Our predictive analytics platform uses behavioral and cultural insights to help sponsors identify the right participants, design culturally relevant outreach, and follow up in ways that keep engagement high throughout the trial.  These tools are supported by our hands-on outreach team, who work directly with communities to turn interest into participation and participation into retention.  ## **Rethinking “Time to Launch”**  [Efficient enrollment strategies](https://blog.acclinate.com/building-trust-in-clinical-trials) that put people first help remove barriers. Building relationships before a trial begins extends beyond making recruitment more inclusive—it makes it more predictable. Sponsors who approach representation as a core part of trial design, rather than an add-on, often find they hit their timelines more reliably and avoid the last-minute chaos that can come with traditional recruitment methods.  It’s a mindset shift: inclusion is an accelerator toward more solvent research studies.  ## **Where to Start**  If you’re ready to improve diversity in clinical trials without slowing progress, consider:  - **Engaging Communities Early** – Don’t wait until recruitment stalls to start outreach. Build relationships during protocol design. - **Investing in Cultural Relevance** – Tailor messaging and education to the specific concerns and priorities of your target populations. - **Leveraging Predictive Insights** – Use tools like e-DICT™ to identify and prioritize high-fit participants before recruitment begins. - **Tracking Retention as a Metric of Success** – Enrollment is only part of the equation; retention determines efficiency.  ## **Closing the Gap Between Equity and Efficiency**  The belief that equity slows clinical trials is rooted in outdated assumptions. In truth, representation and speed can—and should—work hand in hand. By starting early, prioritizing cultural relevance, and leveraging both trust-building and technology, sponsors can incorporate efficient enrollment strategies that hit diversity goals without jeopardizing timelines.  The future of clinical research lies in recognizing that inclusion is not a hurdle to overcome but a strategic advantage. And with partners like Acclinate, that advantage can translate into faster, more reliable, and more impactful results for all.  Representation can be the best driver of clinical trial efficiency. [Schedule a 1:1 meeting with our team](https://www.acclinate.com/request-a-demo) to learn more. ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:23:12.682Z", "datePublished" : "2025-08-28T13:15:00.000Z", "headline" : "How to Improve Diversity in Clinical Trials Without Slowing Progress", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Improve-Diversity-in-Clinical-Trials-Without-Slowing-Progress.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/diversify-clinical-trials-without-slowing-progress-acclinate", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```